Business
PharmaCielo Announces TSX Venture Exchange Approval of Warrant Extension
PharmaCielo Announces TSX Venture Exchange Approval of Warrant Extension Canada...
About this update from Pharmacielo Ltd.
[{"type":"text","content":"\n \n \n \n PharmaCielo Announces TSX Venture Exchange Approval of Warrant Extension\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n TORONTO\n \n and RIONEGRO,\n \n Colombia\n \n \n ,\n \n \n Nov. 22, 2022\n \n \n /CNW/ -\n \n PharmaCielo Ltd.\n \n \n (\"PharmaCielo\" or the \"Company\") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of\n \n Colombia's\n \n premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (\"Holdings\"), today announced\n \n \n that the TSX Venture Exchange (\"TSXV\") has approved the extension of 9,007,200 warrants originally issued on\n \n November 20, 2020\n \n (the \"Warrants\") under the TSX-Venture Symbol PCLO.WT. In accordance with the TSXV's rules for warrant amendments set out in section 3 of Policy 4.1 of the TSXV's Corporate Finance Policies, amendments to warrants listed for trading are not permitted. As such, the Warrants were delisted from trading at market close on\n \n November 21, 2022\n \n , and will be exercisable until\n \n November 20, 2024\n \n . Full details may be found below.\n \n \n \n \n \n \n \n \n \n \n \n Number of Warrants:\n \n 9,007,200 (today), 10,000,000 (originally issued)\n \n \n \n Original Expiry Date of Warrants:\n \n November 20, 2022\n \n \n \n New Expiry Date of Warrants:\n \n November 20, 2024\n \n \n \n Exercise Price of Warrants:\n \n $0.65\n \n \n \n \n About PharmaCielo\n \n \n \n \n \n PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in\n \n Canada\n \n , with a focus on ethical and sustainable cultivating, processing, and supply of all natural, pharmaceutical-grade medical dried cannabis flower and cannabis products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro,\n \n Colombia\n \n .\n \n \n \n \n The board of directors and executive team of PharmaCielo are comprised of a diversely talented gro...